» Articles » PMID: 19228923

Mantle Cell Lymphoma Cells Express High Levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for Interactions with the Stromal Microenvironment and Specific Targeting

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2009 Feb 21
PMID 19228923
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Mantle cell lymphoma (MCL) is characterized by an early, widespread dissemination and residual disease after conventional treatment, but the mechanisms responsible for lymphoma cell motility and drug resistance are largely unknown. There is growing evidence suggesting that chemokine receptors and adhesion molecules are critical for malignant B-cell trafficking and homing to supportive tissue microenvironments, where they receive survival and drug resistance signals. Therefore, we examined chemokine receptor and adhesion molecule expression and function in MCL cells and their importance for migration and adhesion to marrow stromal cells (MSCs). We found that MCL cells display high levels of functional CXCR4 and CXCR5 chemokine receptors and VLA-4 adhesion molecules. We also report that MCL cells adhere and spontaneously migrate beneath MSCs in a CXCR4- and VLA-4-dependent fashion (pseudoemperipolesis). Moreover, we demonstrate that MSCs confer drug resistance to MCL cells, particularly to MCL cells that migrate beneath MSC. To target MCL-MSC interactions, we tested Plerixafor, a CXCR4 antagonist, and natalizumab, a VLA-4 antibody. Both agents blocked functional responses to the respective ligands and inhibited adhesive interactions between MCL cells and MSCs. These findings provide a rationale to further investigate the therapeutic potential of these drugs in MCL.

Citing Articles

Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?.

Ayoub M, Susin S, Bauvois B Cancers (Basel). 2025; 17(1.

PMID: 39796700 PMC: 11719013. DOI: 10.3390/cancers17010072.


A phase I study using bortezomib (Velcade), cladribine, and rituximab in treating patients over 50 years old with mantle cell lymphoma.

Pu J, Berger K, Zheng C, Do N, Claxton D, Ehmann W Front Oncol. 2024; 14:1449401.

PMID: 39737396 PMC: 11683081. DOI: 10.3389/fonc.2024.1449401.


Modeling Lymphoma Angiogenesis, Lymphangiogenesis, and Vessel Co-Option, and the Effects of Inhibition of Lymphoma-Vessel Interactions with an αCD20-EndoP125A Antibody Fusion Protein.

Elledge C, Zhang Y, Shin S, Cho H, Ramakrishnan S, Sankar A Cells. 2024; 13(22).

PMID: 39594584 PMC: 11593053. DOI: 10.3390/cells13221835.


CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.

de Matos Rodrigues J, Lokhande L, Olsson L, Hassan M, Johansson A, Janska A Blood Adv. 2024; 8(16):4370-4385.

PMID: 38959399 PMC: 11375268. DOI: 10.1182/bloodadvances.2023012039.


Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).

Du J, Lin Z, Fu X, Gu X, Lu G, Hou J Cell Commun Signal. 2024; 22(1):177.

PMID: 38475811 PMC: 10935833. DOI: 10.1186/s12964-024-01544-7.


References
1.
Schwickert T, Lindquist R, Shakhar G, Livshits G, Skokos D, Kosco-Vilbois M . In vivo imaging of germinal centres reveals a dynamic open structure. Nature. 2007; 446(7131):83-7. DOI: 10.1038/nature05573. View

2.
Miyake K, Hasunuma Y, Yagita H, Kimoto M . Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture. J Cell Biol. 1992; 119(3):653-62. PMC: 2289667. DOI: 10.1083/jcb.119.3.653. View

3.
Burger J, Burger M, Kipps T . Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999; 94(11):3658-67. View

4.
Campbell D, Kim C, Butcher E . Chemokines in the systemic organization of immunity. Immunol Rev. 2003; 195:58-71. DOI: 10.1034/j.1600-065x.2003.00067.x. View

5.
Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23. PMC: 9103713. DOI: 10.1056/NEJMoa0802885. View